|
SEPR
Sepracor
Inc. is a research-based pharmaceutical company dedicated to treating and
preventing human disease through the discovery, development and commercialization
of pharmaceutical compounds, including product candidates directed toward
serving unmet medical needs
Sepracor
Inc. Sets Conference Call and Webcast for First Quarter 2007 Operating
Results
MARLBOROUGH,
Mass.--(BUSINESS WIRE)--April 9, 2007--Sepracor Inc. (Nasdaq: SEPR) will
announce its first quarter 2007 financial results on April 24, 2007. In
conjunction with the press release, Sepracor will host a conference call
and live webcast beginning at 8:30 a.m. ET on April 24, 2007 to discuss
its first quarter 2007 financial results.
Sepracor
Announces Fourth Quarter and Full Year 2006 Results
2006
Product Revenues Increased by 51% Over 2005
MARLBOROUGH,
Mass., Jan 31, 2007 (BUSINESS WIRE) -- Sepracor Inc. (Nasdaq: SEPR) today
announced its consolidated financial results for the fourth quarter and
full year 2006.
For
the three months ended December 31, 2006, Sepracor's consolidated revenues
were approximately $357.2 million, of which revenues from Sepracor's pharmaceutical
product sales were approximately $348.8 million (XOPENEX(R) brand levalbuterol
HCl Inhalation Solution revenues were $179.9 million, XOPENEX HFA(R) brand
levalbuterol tartrate Inhalation Aerosol MDI revenues were $20.9 million
and LUNESTA(R) brand eszopiclone revenues were $148.0 million). Net income
for the fourth quarter of 2006 was approximately $99.1 million, or $0.85
per diluted share. Reported results for the fourth quarter of 2006 included
charges of $13.8 million, or $0.12 per diluted share, for stock-based compensation
due to Sepracor's adoption in January 2006 of Statement of Financial Accounting
Standards, or SFAS No. 123R. These consolidated results compare with consolidated
revenues of $311.1 million, of which revenues from Sepracor's pharmaceutical
product sales were approximately $302.9 million (XOPENEX Inhalation Solution
revenues were $146.0 million, XOPENEX HFA revenues were $12.0 million and
LUNESTA revenues were $144.9 million), and a net income of $36.9 million,
or $0.31 per diluted share, for the three months ended December 31, 2005.
For
the year ended December 31, 2006, Sepracor's consolidated revenues were
approximately $1,196.5 million, of which revenues from Sepracor's pharmaceutical
product sales were approximately $1,162.8 million (XOPENEX Inhalation Solution
revenues were $555.0 million, XOPENEX HFA revenues were $41.0 million and
LUNESTA revenues were $566.8 million). Net income for the year ended December
31, 2006 was approximately $184.6 million, or $1.60 per diluted share.
Reported results for the full year 2006 included charges of $45.2 million,
or $0.39 per diluted share, for stock-based compensation due to Sepracor's
adoption of SFAS No. 123R. These consolidated results compare with consolidated
revenues of $820.9 million, of which Sepracor's pharmaceutical product
sales were approximately $769.7 million (XOPENEX Inhalation Solution revenues
were $428.5 million, XOPENEX HFA revenues were $12.0 million and LUNESTA
revenues were $329.2 million) and a net income of $3.9 million, or $0.03
per diluted share, for the year ended December 31, 2005.
As
of December 31, 2006, Sepracor had approximately $1,166 million in cash
and short- and long-term investments. Sepracor expects to spend approximately
$451 million, including $11 million in interest, to repay all of its outstanding
5% convertible subordinated debentures when they come due on February 15,
2007
|
